Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Zelasudil (RXC007) in Healthy Males
NCT04931147Phase 1Completed
- Sponsor
- Redx Pharma
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zelasudil in idiopathic pulmonary fibrosis (IPF) and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Redx Pharma. Primary endpoints: Treatment Emergent Adverse Events up to 8 weeks, Number of participants with abnormal laboratory values up to 8 weeks and 2 more. Started May 2021; status: completed.
02
Drugs
zelasudil
03
Conditions
idiopathic pulmonary fibrosis (IPF)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04931147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931147.